IFNA1 and COVID-19: Despite one study found a negative impact of GA on immune response to Influenza vaccine, it was not replicated in subsequent studies, and so it seems safe to administer a vaccine against SARS-CoV-2 in MS patients treated with both IFN or GA [96,98] Similarly, based on previous observations from Influenza vaccine responses in MS patients treated with teriflunomide [99] and confirmed seroconversion after COVID-19 [37], a successful vaccination can be anticipated in patients treated with teriflunomide [38].